Revised Response Criteria for Malignant Lymphoma
Bruce D. Cheson, Beate Pfistner, Malik Eid Juweid et al. · Journal of Clinical Oncology · 2007
PURPOSE: Standardized response criteria are needed to interpret and compare clinical trials and for approval of new therapeutic agents by regulatory agencies. METHODS: The International Working Group response criteria (Cheson et al, J Clin Oncol 17:1244, 1999) were widely adopted, but required reassessment because of identified limitations and the increased use of [18F]fluorodeoxyglucose-positron emission tomography (PET), immunohistochemistry (IHC), and flow cytometry. The International Harmonization Project was convened to provide updated recommendations. RESULTS: New guidelines are presented incorporating PET, IHC, and flow cytometry for definitions of response in non-Hodgkin's and Hodgkin's lymphoma. Standardized definitions of end points are provided. CONCLUSION: We hope that these guidelines will be adopted widely by study groups, pharmaceutical and biotechnology companies, and regulatory agencies to facilitate the development of new and more effective therapies to improve the outcome of patients with lymphoma.
Cited by 4,426 works. doi:10.1200/jco.2006.09.2403 Open-access PDF
Authors
- Bruce D. Cheson
- Beate Pfistner
- Malik Eid Juweid
- Randy D. Gascoyne
- Lena Specht
- Sandra J. Horning
- Bertrand Coiffier
- Richard I. Fisher
- Anton Hagenbeek
- Emanuele Zucca
- Steven T. Rosen
- Sigrid G. Stroobants
- T. Andrew Lister
- Richard T. Hoppe
- Martin H. Dreyling
- Kensei Tobinai
- Julie Marie Vose
- Joseph M. Connors
- Massimo Federico
- Volker Diehl
References
- Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
- Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori
- Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
- FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
- Whole-Body Positron Emission Tomography Using18F-Fluorodeoxyglucose for Posttreatment Evaluation in Hodgkin’s Disease and Non-Hodgkin’s Lymphoma Has Higher Diagnostic and Prognostic Value Than Classical Computed Tomography Scan Imaging
- Positron-Emission Tomography and Assessment of Cancer Therapy
- Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
- Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([18F]FDG) After First-Line Chemotherapy in Non-Hodgkin’s Lymphoma: Is [18F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods?
- [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome
- PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.